论文部分内容阅读
目的探讨美沙拉嗪联合清肠化浊汤治疗轻中度远段溃疡性结肠炎(DUC)的效果及安全性,为提高DUC临床疗效提供参考。方法 128例轻中度远段溃疡性结肠炎患者按随机数字表法分为对照组和观察组,各64例。对照组在对症基础治疗上予以美沙拉嗪口服治疗,1.0 g/次,4次/d,口服;观察组在对照组治疗基础上加用清肠化浊汤治疗,100 ml/次,每晚睡前灌肠。两组均治疗2周。治疗结束后比较两组疾病的活动指数(DAI)、结肠镜下黏膜病变程度和临床疗效,并记录患者在治疗过程中不良反应发生情况。结果两组治疗后DAI降低,结肠镜下黏膜病变程度减轻,以观察组为著,差异有统计学意义(均P<0.05);观察组临床总有效率(96.88%)明显高于对照组(84.38%),差异有统计学意义(P<0.05);两组均无明显严重不良反应发生。结论美沙拉嗪口服联合清肠化浊汤可提高轻中度DUC的临床疗效,安全性较好。
Objective To investigate the efficacy and safety of mesalazine combined with Qingchang Huazhuo Decoction in the treatment of mild to moderate distal ulcerative colitis (DUC), and provide references for improving the clinical efficacy of DUC. Methods 128 patients with mild to moderate distal ulcerative colitis were divided into control group and observation group according to random number table method, with 64 cases in each group. The control group was treated with mesalazine orally at 1.0 g / time, 4 times / d on the basis of symptomatic treatment. The observation group was treated with Qingchang Huazhuo Decoction on the basis of the control group, 100ml / time per night Bedtime enema. Both groups were treated for 2 weeks. After the treatment, the activity index (DAI), colon mucosal lesion degree and clinical curative effect were compared between the two groups, and the incidence of adverse reactions in the patients during the treatment was recorded. Results After treatment, the DAI decreased and the degree of colon mucosal lesion decreased in the two groups (all P <0.05). The total clinical effective rate (96.88%) in the observation group was significantly higher than that in the control group 84.38%), the difference was statistically significant (P <0.05); no serious adverse reactions occurred in both groups. Conclusion Mesalazine combined with Qingchang Huazhuo decoction can improve the clinical efficacy of mild to moderate DUC with good safety.